Sandoz Canada Supports Ontario’s Biosimilars Switching Policy
Shots
- The Ontario government has approved the use of more biosimilar drug treatments & establish a biosimilar switching policy to improve patient access to quality medicines. The transition will begin Mar 2023 & completed at the end of 2023
- Ontario drug benefit recipients who are on an originator biologic (prescription drug) will begin to transition to a Health Canada-approved biosimilar version of the drug & the program will initially focus on reference biologics for chronic conditions i.e., arthritis, diabetes, inflammatory bowel disease & psoriasis
- Sandoz Canada supports patients, healthcare professionals & Ontario Government with quality biosimilar medicines and patient support programs & currently has 6 biosimilars in Canada (Omitrope, Erelzi, Riximyo, Hyrimoz, Ziextenzo & Inclunox)
Ref: Globenewswire | Image: Sandoz
Related News:- Sandoz Canada Congratulates the Quebec Government on Implementing a Shift Towards Biosimilars
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
